Advanced Therapeutic Options for Multiple Sclerosis Management
Explore the latest treatment options for multiple sclerosis, including FDA-approved disease-modifying drugs such as Gilenya, Teriflunomide, and Dimethyl Fumarate. These therapies effectively reduce relapse rates and slow disease progression, offering hope to patients with relapsing MS. Understanding these treatments can aid in informed decision-making and improve management strategies for this chronic condition.
Managing multiple sclerosis involves addressing both the root immune dysfunction and alleviating symptoms. Immunomodulatory therapies (IMT) aim to reduce relapse frequency and slow disease progression. These disease-modifying treatments (DMTs) are primarily used for relapsing forms of MS, and their use depends on patient response and tolerability. FDA-approved medications like Gilenya, introduced in 2010, have shown to cut relapses by half and slow progression. Other options include Teriflunomide (approved in 2012), which decreases disease advancement, and Dimethyl Fumarate (approved in 2013), which shields nerves from immune attack, functioning as an antioxidant-like protector.
Multiple Sclerosis Treatment
Immunomodulatory Therapy
Disease-Modifying Drugs
FDA Approved MS Medications
